Northwestern: Diabetes drug metformin shows potential benefit in large COVID-19 trial
August 19, 2022
August 19, 2022
EVANSTON, Illinois, Aug. 19 (TNSjou) -- Northwestern University issued the following news release:
* * *
Ivermectin and fluvoxamine--also tested in multi-site clinical trial--were not effective
* None of the drugs in the trial prevented the primary outcome (which included low oxygen levels on a home oxygen monitor); for a secondary outcome, metformin lowered odds of emergency visits, hospitalizations, death by over 40%
* Trial is one of the lar . . .
* * *
Ivermectin and fluvoxamine--also tested in multi-site clinical trial--were not effective
* None of the drugs in the trial prevented the primary outcome (which included low oxygen levels on a home oxygen monitor); for a secondary outcome, metformin lowered odds of emergency visits, hospitalizations, death by over 40%
* Trial is one of the lar . . .